Abstract Based on meta-analyses and the results of several trials, adjuvant chemotherapy is currently recommended for stage II and stage III non-small cell lung cancer (NSCLC) patients after complete tumor resection, and may be considered for patients with stage IB NSCLC ≥ 4 cm. As individualized therapy becomes integrated into the care of advanced NSCLC, its role in early stage NSCLC and, in particular, in the adjuvant setting, also will become of greater importance. In the adjuvant setting, prognostic and predictive biomarkers might identify which patients have a worse prognosis and, among them, those who could benefit from customized chemotherapy. In the present review, we summarized the available data and ongoing trials testing the role of individualized adjuvant therapy (chemotherapy, targeted therapy and immunotherapy) in NSCLC.
Introduction
Lung cancer remains the leading cause of cancer death worldwide, with 226,000 new cases and 160,000 deaths in the US in 2012 and more than 1.2 millions deaths in the world yearly. Globally, 5-year survival remains around 16 %. Until recently, surgery alone was the standard care for patients with stage I-IIIA non small cell lung cancer (NSCLC), resulting in survival rates from 23 % in stage IIIA, 33 % in stage IIB and up to 89 % in stages IA [1] . In 1995, a large meta-analysis, pooling individualized data from randomized trials of adjuvant chemotherapy vs. best supportive care (BSC), showed a trend for prolonged overall survival (OS) with adjuvant chemotherapy, especially with platinum based regiments, but the differences were not statistically significant. [2] . Thus, the evidence was not felt to be adequate to recommend adjuvant chemotherapy after complete surgical resection. However, the results of this meta-analysis prompted several randomized trials testing adjuvant chemotherapy in completely resected NSCLC, using newer and more active chemotherapeutic agents combined with a platinum analogue. Several large international trials demonstrated statistically significant survival benefits with adjuvant chemotherapy, including the International Adjuvant Lung Cancer Trial (IALT) [3] , the National Cancer Institute of Canada Clinical Trials Group JBR.10 (NCIC-CTG JBR.10) trial [4] , the Adjuvant Navelbine International Trial Association (ANITA) study [5] , and the Cancer and Leukemia Group B (CALBG) 9633 trial [6] . The IALT trial was the first to show a benefit of postoperative cisplatin-based adjuvant chemotherapy [3] . Subsequently, both JBR.10 and ANITA confirmed reported significant prolongation of survival with cisplatin/vinorelbine [4, 5] . As three large randomized trials with similar design showed consistent results, adjuvant chemotherapy based on a cisplatin doublet is recommended in stage II-IIIA NSCLC with a level 1 of evidence [7] [8] [9] . In addition, the LACE (Lung Adjuvant Cisplatin Evaluation) metaanalysis pooling individual patient data from five trials (IALT, JBR.10, ANITA, CALGB-9633 and the Spanish NATCH trials) [10••] , as well as an update of the 1995 meta-analysis [11] , confirmed that adjuvant chemotherapy increases survival in stage II and stage IIIA. The LACE meta-analyses demonstrated an absolute decrease of 6.9 % for lung cancer death and an absolute increase of 5.4 % for overall survival at 5 years in patients with completely resected NSCLC [10••] . The updated meta-analyses continued to confirm a 5 % increase of survival at 5 years [11] . The LACE meta-analysis also showed a nonsignificant survival benefit in stage IIB [10••] , but a potentially detrimental effect in stage IA [10••] . CALGB-9633, which was limited to stage IB, demonstrated a significant global benefit in disease-free survival (DFS), as well as overall survival and DFS in an unplanned subset analysis of patients with tumors of 4 cm or more [6] . Based on these meta-analyses and the results of several individual trials, adjuvant chemotherapy now is recommended to fit patients with stage II and stage III NSCLC after complete tumor resection, and may be considered for patients with stage IB NSCLC ≥ 4 cm [7] [8] [9] .
Despite improvements in survival with adjuvant chemotherapy after surgical resection of localized NSCLC, giving a survival advantage of approximately 5 % at 5 years, there is still a relatively high risk of relapse, even for early-stage NSCLC. Up to 40 % of all stage IB, and 60 % of stage II patients relapse and die from lung cancer despite receiving adjuvant chemotherapy [6] . This suggests that more sensitive biomarkers are needed to identify the subgroups of patients at extremely high risk, and to develop strategies to enhance their treatment. Initially tested and integrated into the treatment selection for advanced NSCLC, individualized therapy may also play a role in the adjuvant setting. The integration of prognostic and predictive biomarkers has the potential to identify which patients are cured with surgery alone and who do not need further therapy; and conversely, which patients may derive the greatest benefit from chemotherapy, and in particular, customized treatment based on individual tumor profiling. The present review aims to analyze the available published data and the ongoing trials testing the role of individualized therapy in the adjuvant setting of NSCLC.
Individualized therapy in adjuvant therapy
Here we review the current status of prognostic biomarkers for completely resected NSCLC and predictive biomarkers for adjuvant chemotherapy, targeted therapy and immunotherapy of patients who underwent a complete resection for an early stage NSCLC. Translational research projects for JBR.10, the International Adjuvant Lung Cancer Trial Biologic Program (IALT-Bio), and the Lung Adjuvant Cisplatin Evaluation Biologic Program (LACE-Bio) attempted to characterize and/or validate these biomarkers for the selection of those patients who and do not benefit from adjuvant chemotherapy. Only few data are available about targeted therapy, mainly one study (BR.19) about Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and one trail for immunotherapy. The results of the concluded studies of this section are shown in Table 1 . The ongoing trials are described in Table 2 .
Chemotherapy

DNA repair and DNA replication
Resected early stage lung tumors, compared with corresponding normal lung tissue, frequently exhibit significant transcript overexpression of genes belonging to double strand DNA break repair (e.g. BRCA1, XRCC2) pathways and DNA replication (e.g. TS, RRM1) pathways [12] . Transcriptional overexpression of some of these genes has shown strong correlation with more aggressive clinical behavior, and potentially may explain reduced sensitivity to chemotherapy. To date, there is preliminary evidence from studies in advanced NSCLC to suggest that both excision repair cross-complementing rodent repair deficiency, complementation group 1 (ERCC1), ribonucleotide reductase M1 (RRM1) and Breast Cancer 1 (BRCA1) may be prognostic and predictive, and that they may play a role in selecting tailored chemotherapy in advanced stage NSCLC. Prospectively accrued patients treated with a 'customized therapy' approach based on RMM1 and ERCC1 mRNA tumor expression levels were compared to 'standard, noncustomized therapy' approaches [13] . ERCC1/RMM1 customized chemotherapy appeared to be a predictor of improved overall survival in the multivariable Cox proportional hazards model analysis. Another prospective non-randomized customized chemotherapy trial based on BRCA1 expression levels was associated with good overall survival for both cisplatin plus gemcitibine in patients with low levels of BRCA1 mRNA and taxanes in patients with high levels of BRCA1 [14] .
ERCC1 Cisplatin establishes covalent cross-links between DNA strands, and thereby inhibits DNA replication. This cisplatin-induced DNA damage can be repaired by several DNA repair mechanisms, including nucleotide excision repair (NER). ERCC1 is a key protein involved in the NER complex. High DNA repair capacity eliminates cisplatin-induced DNA adducts and thus leads to platinum resistance. Within IALT-Bio, ERCC1 expression was assessed retrospectively by immunohistochemistry (IHC) on tumor tissue [15] . High ERCC1 expression was shown to be a favorable prognostic factor in patients not receiving adjuvant chemotherapy. On the other hand, adjuvant cisplatin-based chemotherapy was associated with longer overall survival compared to observation alone in ERCC1 negative tumors (HR00.65, p00.002), but not in ERCC1 positive tumors (HR01.14, p00.40), This qualitative interaction was highly significant (interaction p0 0.009) [15] . Recent analyses of ERCC1 expression in various histologic subtypes suggest that this cisplatin efficacy might be limited to squamous cell carcinoma with low ERCC1 expression [16] . Although these results are encouraging, validation is required before ERCC-1 expression (IHC or RT-PCR) can be recommended for clinical use, and currently, LACE-Bio is performing retrospective validation of this ERCC1 protein expression. Several prospective randomized trials, such as the Tailored Post-Surgical Therapy in Early Stage NSCLC (TASTE), Southwest Oncology Group SWOG-0720 and the International Tailored Chemotherapy Adjuvant (ITACA) trials, are testing the feasibility and use of ERCC1 as a predictive biomarker in the adjuvant setting (Table 1) . TASTE is a Phase II/III trial comparing adjuvant chemotherapy (cisplatin/pemetrexed) with customized adjuvant treatment, based on EGFR mutation status and ERCC1 IHC expression in stage II-IIIA non-squamous NSCLC. SWOG-0720 is a Phase II feasibility trial based on ERCC1/ RMM1 expression in stage I NSCLC. ITACA is a Phase III trial comparing customized adjuvant chemotherapy based on ERCC1 and thymidylate synthase (TS) gene expression in stage II-IIIA NSCLC to standard chemotherapy. [17] and reported that adjuvant cisplatin-based chemotherapy was associated with a trend towards improved OS compared to observation in patients with tumors with low MSH2 expression (HR00.76, p00.03), while no difference in OS was observed in the high MSH2 group (HR01.12, p00.48, interaction p00.06).
BRAC1 BRCA1 plays a central role in DNA repair and also is involved in mitosis and cell division. BRCA1 mRNA level is has been reported to be prognostic in patients who underwent resection for early stage NSCLC, with high expression associated with shorter overall survival compared to low expression (HR01.98, p00.02) [18] . In the Phase II nonrandomized pilot Spanish Customized Adjuvant Treatment (pilot SCAT) trial, treating with single-agent docetaxel without a platinum analogue in BRCA1 high expression had no detrimental effect on survival, compared to cisplatin/ gemcitibine in BRCA1 low expression [19] . These observations form the basis of the validation randomized Phase III Spanish Customized Adjuvant Treatment (validation SCAT) trial in resected stage II-III NSCLC, testing standard adjuvant chemotherapy (cisplatin/docetaxel) vs. customized adjuvant chemotherapy based on BRCA1 mRNA expression as previously done in the pilot SCAT.
RRM1
Ribonucleotide reductase is important for DNA synthesis. High RRM1 expression has been reported to be a good prognostic factor for overall survival in patients who underwent a resection for early stage NSCLC [20] . RRM1 may be a biomarker for gemcitabine chemotherapy. Whether RRM1 is predictive in the adjuvant chemotherapy setting is currently being evaluated in SWOG-0720.
TS TS is an important enzyme in the DNA replication and repair mechanisms. Low TS is a prognostic marker for longer survival in resected NSCLC [21] . TS is also a target of newer antifolate drugs such as pemetrexed [22] . High TS expression is associated with reduced efficacy of pemetrexed in vitro [23] . The predictive value of combined ERCC1 and TS profiles in resected NSCLC is being studied prospectively in the randomized Phase III ITACA trial.
Regulation of cell cycle, apoptosis and mitosis p27 The p27 protein is a member of the cyclin-dependent kinase inhibitory family of proteins that prevent transition from the G1-phase to the S-phase of the cell cycle. Overexpression of p27 may confer de novo resistance to cisplatin by giving necessary time to repair cisplatin-induced DNA p53 The protein encoded by the tumor suppressor gene p53 binds to DNA and plays a role in cell cycle regulation, induction of apoptosis and stabilization of the genome. The role of p53 has been studied both at the protein and DNA level. In JBR.10, p53 protein expression (> 15 %) was a poor prognostic factor (HR01.89, p00.03) and also a predictor of outcome with cisplatin/vinorelbine adjuvant chemotherapy. Patients with p53 IHC positive tumors derived significant benefit from adjuvant therapy (HR 0.54, p00.02), but patients with p53 negative tumors did not (HR01.4, p00.26, interaction p00.02) [26] . However, validation studies from LACE-Bio failed to confirm significant interaction for p53 protein expression (HR00.82, p00.03 and HR 00.87, p 00.22, for p53 negative and positive patients, respectively, interaction p00.64). The p53 mutation was not a prognostic factor (HR01.15, p00.45) in the JBR.10 and not predictive for response to adjuvant chemotherapy (HR00.67, p 00.04 and HR 00.78, p 00.35, for patients with p53 wild type and mutated, respectively, interaction p00.65). The absence of predictive role for p53 mutation was confirmed in the LACE-Bio (HR00.79, p0 0.03 and HR01.03, p00.80, for patients with p53 wild type and mutated, respectively, interaction p00.12) and adjuvant chemotherapy [27] .
Bax Bax is a pro-apoptotic factor that is activated by p53. In a pooled analysis of IALT-Bio and JBR.10 specimens, Bax protein expression by IHC was significantly predictive for benefit from adjuvant chemotherapy on overall survival (HR01.13, p00.31 and HR00.72, p00.007, for Bax negative and positive patients, respectively, interaction p00.009) [28] .
TUBB3 Class III beta-tubulin (TUBB3) is a building block for microtubules. Tubulin-targeting agents (such as taxanes and vinca alkaloids) disrupt normal microtubule function and cause mitosis arrest. High TUBB3 protein expression is associated with non-squamous cell lung carcinoma and KRAS mutation [29] . In JBR.10, high TUBB3 expression was associated a borderline better prognostic in the observation arm (p00.08), but did not predict response to adjuvant chemotherapy (interaction test p00.25) [30] . The LACE-Bio cross-validation study confirmed the absence of predictive effect for high TUBB3 (interaction test p00.81) [31] .
KRAS KRAS, a member of the RAS family of oncogenes, encodes a protein that is involved in signal transduction modulating the cell cycle and resulting in cell proliferation and survival. KRAS mutations in codons 12 and 13 have been reported in up to 25 % of lung adenocarcinoma. In JBR.10, KRAS mutation was not a significant prognostic marker for survival [26] . Wild-type KRAS status was associated with a survival benefit from adjuvant chemotherapy compared to observation only (HR00.69, p00.03), whereas patients with a KRAS mutation did not appear to benefit from adjuvant chemotherapy (HR00.95, p00.87). However, the interaction was not significant (interaction p00.29) [26] . In the LACE-Bio pooled validation study, neither a prognostic nor a predictive effect of KRAS mutation status could be derived (HR00.89, p00.20 and HR01.02, p00.91, for KRAS wild type or mutated, respectively, interaction p00.50) [32] .
Targeted therapy
Novel targeted therapies, such as inhibitors of epidermal growth factor receptor (EGFR), angiogenesis inhibitors, and immunotherapy, have demonstrated effect in advanced NSCLC and are now the focus of studies in the early disease setting as adjuvant therapy.
EGFR
EGFR TKIs were the first molecularly targeted therapies approved to treat NSCLC and were initially studied in unselected patients as second-line and third-line treatment; the ISEL trial [33] evaluated the effect of gefitinib vs. best supportive care (BSC) and the BR.21 trial [34] erlotinib vs. BSC. Patients with certain clinical characteristics, such as adenocarcinoma histology, never-smokers, female sex, and Asian ethnicity, displayed increased sensitivity to EGFR TKIs [35] . Although clinical characteristics may help identify patients who are more likely to benefit from an EGFR TKI, it is crucial that patients are selected for this type of therapy based on measurable biologic characteristics. In the search for molecular mechanisms explaining the better response in certain clinical subgroups, tumorassociated mutations in the tyrosine kinase domain of EGFR were found to be associated with response to EGFR TKIs [36] [37] [38] . The most common EGFR-sensitizing mutations encompass deletions in exon 19 and a point mutation at L858R in exon 21; together, they account for approximately 85 % of EGFR mutations in NSCLC [35] . Other studies have indicated that increased EGFR copy number and EGFR protein expression may also be predictive of response to EGFR TKIs [39] .
In the adjuvant setting, the patients with EGFR mutations in the JBR.10 trial had a potential but not significant benefit to chemotherapy (HR00.44, p00.22, interaction p00.50. The nonsignificant difference can be explained by the low number of patients with EGFR mutations in the JBR.10. However, these results indicate that patients with EGFR mutations should not be treated with EGFR TKIs alone at this time and should be included in clinical trials [40] .
In the BR.19 Phase III randomized trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA NSCLC, no survival benefit over placebo was observed in unselected patients (HR01.24, p00.14 and 1.22, p00.15 for OS and DFS, respectively). Although not powered to draw any conclusions, even the subgroup of patients with EGFR-mutant tumors did not show any benefit from gefitinib treatment (HR for OS 1.58, p00.16) [41•]. The trial was closed prematurely on the basis of the negative results of the ISEL and SWOG-0023 trials. Contrary to this, a retrospective study by Janjigian et al. observed a trend, although not statistically significant, toward improved disease-free survival (DFS) among patients with resected stages I-III lung adenocarcinomas harboring EGFR-mutations who received EGFR tyrosine kinase inhibitors (TKIs) as adjuvant therapy compared with patients who did not receive adjuvant TKI. The 2-year DFS was 89 % for patients treated with adjuvant TKI compared with 72 % in the control group (HR00.53, p00.06). The 2-year overall survival was 96 % with adjuvant EGFR TKI and 90 % in the control group (HR00.62; p00.296) [42] . A Phase III trial is currently evaluating gefitinib vs. vinorelbine/platinum as adjuvant treatment in stage II-IIIA (N1-N2) NSCLC with EGFR mutation.
Erlotinib is another EGFR TKI in under evaluation in the ongoing Phase III Randomized Double-Blind Trial in Adjuvant NSCLC with erlotinib (RADIANT) study. Patients with resected stage IB-IIIA NSCLC who are EGFR-positive by IHC and/or fluorescent in situ hybridization (FISH) are randomized to erlotinib or placebo for 2 years after surgical resection and optional adjuvant chemotherapy. Accrual is complete and final results are awaited. Another ongoing study, the Phase II SELECT trial, is evaluating adjuvant erlotinib for two years in patients with resected, early-stage NSCLC (stage IA-IIIA) and confirmed mutations in EGFR [43] .
The Tailored Post-Surgical Therapy in Early Stage NSCLC (TASTE) trial is a Phase II/III study randomizing patients with stage II-IIIA (non-N2) resected nonsquamous NSCLC to a non-customized standard adjuvant chemotherapy arm and a genotypic arm, in which patients with known EGFR activating mutations receive erlotinib for 1 year, while those who have wild-type EGFR receive chemotherapy based on the level of ERCC1 expression, with low levels of ERCC1 being treated with cisplatin/pemetrexed and high levels of ERCC1 with non-platinum based chemotherapy.
Angiogenesis inhibition
Vascular endothelial growth factor (VEGF) stimulates angiogenesis, which is essential for tumor growth and progression [44] . Overexpression of VEGF is common in NSCLC and is associated with adverse clinical outcomes. Bevacizumab is a recombinant humanized monoclonal antibody against VEFG that inhibits angiogenesis [45] . It has been evaluated in combination with chemotherapy in advanced NSCLC, and has demonstrated modest clinical benefit in two large trials [46, 47] . Based on these studies, the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) approved bevacizumab in combination with platinum-based chemotherapy as a first-line treatment option for advanced non-squamous NSCLC. No prospectively useful predictive biomarkers for treatment response to bevacizumab have been identified so far. Existing data indicate a possible predictive role for single nucleotide polymorphisms (SNPs) in the VEGF signaling pathway, as well as treatment-emergent hypertension, but the clinical importance of this remains to be evaluated [48] . However, another VEGF receptor inhibitor, cediranib, showed no predictive association for hypertension in the NCIC Clinical Trials Group study BR24 [49] .
The role of bevacizumab in the adjuvant setting of NSCLC currently is being evaluated in ECOG-1505. In this trial, patients with resected stage IB (≥ 4 cm), II, and IIIA NSCLC are randomized to four cycles of adjuvant platinumbased doublet chemotherapy with or without bevacizumab for one year. Patients with squamous histology are included in this trial because resection of the primary tumor eliminates the source for potential tumor-related hemorrhage. In the adjuvant setting, there may be concerns with bevacizumab treatment for wound healing, as well as toxicities such as hemorrhage, hypertension and thrombotic events. Interim safety data including 557 patients reported no unexpected toxicities with a significant increase in risk of grades 3/4 hypertension (0.7 % vs. 19.7 %, p <0.001), proteinuria (0.7 % vs. 3.4 %, p00.03), abdominal pain (0.4 % vs. 4.6 %, p00.001), and overall grade 3/4 toxicity (68.5 % vs. 83.4 %, p<0.001) associated with bevacizumab. One case each of fatal hemoptysis and nonfatal bronchopleural fistula were seen in patients receiving bevacizumab [50] .
Novel targets
With the rapid development of molecular techniques to analyze genetic aberrations in tumors, a greater understanding of the molecular mechanisms behind tumorigenesis and the identification of new therapeutic targets has stimulated the development of novel agents with the potential to improve the standard chemotherapy regimens for NSCLC. So far, these novel targeted agents have been or are currently evaluated in advanced disease, but it also will be of great interest to study these agents in the adjuvant setting once their efficacy in advanced NSCLC has been confirmed. In 2007, Soda and colleagues identified the echinoderm microtubule associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion gene in a subset of patients with NSCLC [51] . This genetic alteration originates from a translocation within chromosome 2p that leads the intracellular tyrosine kinase domain of ALK to fuse with various (N-terminal) truncated portions of EML4, resulting in constitutively enhanced ALK activity, which stimulates tumor growth. Various reports indicate that 1.6-8.6 % of patients with NSCLC are ALK-positive [52] . In 2011, the FDA approved crizotinib, an ALK kinase inhibitor, for use in patients with ALK-positive NSCLC on FISH analysis. The approval was based on data from an early-stage single arm 82 patient trial that reported an overall response rate of 57 % to crizotinib, including one confirmed complete response and 33 % of patients with stable disease in patients with the mutation [53] . An updated analysis of this study showed that 87 of 143 patients had an objective response (60.8 %), including three complete responses and 84 partial responses. Median PFS was 9.7 months, whereas for median OS data are not yet mature, but estimated OS at 6 and 12 months was 87.9 % and 74.8 %, respectively [54] .
Other novel targets of potential interest in the adjuvant setting include ROS1, which was identified as a transforming fusion gene with the 5´region of SLC34A2 or the 5´region of CD74 [55] , and RET showing in-frame fusion transcripts with KIF5B (the kinesin family 5B gene) or CCDC6 leading to constitutively active RET kinase [56, 57] .
Individualized immunotherapy
Recently, promising results have been obtained with immunotherapy in the context of the adjuvant setting of NSCLC. A hypothetic explanation for the success of immunotherapy in the adjuvant setting as compared to advanced disease could be the lower tumor tolerance for immune response for smaller volume of tumor cells [58] . Cancer vaccines, including antigen-specific, tumor-cell specific and dendritic-cell-based vaccines, have been developed. In particular, two vaccines, the antigen-specific melanoma-associated antigen 3 (MAGE-A3) vaccine (MAGE-A3 ASCI) and the liposomal BLP25 vaccine (L-BLP25) targeting MUC1 are being tested in Phase III trials in patients with early NSCLC (Table 2) .
MAGE-A3 is a tumor specific antigen expressed in 35-50 % of NSCLC [59, 60] . A total of 182 patients, all MAGE-A3 positive (assessed by RT-PCR expression on fresh tissue), stage IB/II NSCLC were treated postoperatively with either MAGE-A3 ASCI or placebo [60] . A trend toward longer disease-free interval (HR00.74, p00.107), DFS (HR00.73, p00.093) and OS (HR00.66, p00.088) were observed in patients treated with MAGE-A3 ASCI. An ongoing large Phase III placebo controlled trial has completed accrual of more than 2,000 patients; MAGRIT (MAGE-A3 as Adjuvant non small cell lunG cancer ImmunoTherapy) has completed accrual and results are awaited [61] .
MUC1 is a cell surface protein glycoprotein that is overexpressed in several cancers, including NSCLC [62] . The L-BLP25 vaccine is a liposomal molecule targeting MUC1. A Phase II trial compared L-BLP25 plus best supportive care (BSC) to BSC alone after chemotherapy in patients with stage IIIB/IV NSCLC. This study showed a trend for longer median OS (HR00.55, p00.16) in the subgroup of patients with loco-regional stage IIIB treated with L-BLP25 [63, 64] . The Phase III placebo controlled trial, the Stimulating Targeted Angiogenic Responses to NSCLC Trial (START), evaluates L-BLP25 in patients with unresectable stage III with an objective response or a stable disease after a first line of chemotherapy [65] . START has completed accrual and results are awaited.
A role for panel of biomarkers Panels of biomarkers or signatures may be used to predict prognosis or response to therapy. However, to date all signatures lack sufficient validation to be implemented in clinical practice.
In early NSCLC, Zhu et al. analyzed the role of a prognostic 15-gene signature derived from patients participating in JBR.10. This signature identified patients at high and low risk within the observation arm (HR 013.32 (2.86-62.11), p<0.0001 and HR013.47 (3.00-60.43), p<0.0001, for stage IB and stage II patients, respectively). Furthermore, high-risk patients derived significant benefit from chemotherapy (HR00.33, CI 0.17-0.63, p00.0005), but not in those at lowrisk where chemotherapy was detrimental as compared to observation (HR03.67, CI 1.22-11.06, p00.0133; interaction p00.0001) [66] . These results require validation in other studies, but few randomized trials have frozen sample tumor banks to perform the necessary microarray studies. Attempts to translate the signature to paraffin-embedded samples are ongoing.
Conclusions
Despite improvements in survival with adjuvant chemotherapy after complete resection of localized NSCLC, giving a survival advantage of approximately 5 % at 5 years, there is still a relatively high risk of relapse even for early-stage NSCLC. Therefore, efforts are ongoing to identify new therapies in the adjuvant setting and in the new era of personalized medicine to select patients for individualized treatment on the basis of biomarkers. In the heterogeneous patient population of surgically resected patients, it would be of great value to identify those patients who are most likely to benefit from adjuvant therapy and to match these patients with a biomarker-driven targeted therapy.
